Stock GLAXO GLAXOSMITHKLINE PAKISTAN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials GlaxoSmithKline Pakistan Limited

Equities

GLAXO

PK0001301016

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
100.4 PKR +2.43% Intraday chart for GlaxoSmithKline Pakistan Limited +9.73% +20.98%
Apr. 01 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 35,885 51,136 61,092 43,474 27,952 26,430
Enterprise Value (EV) 1 32,452 48,498 55,079 35,045 23,543 23,544
P/E ratio 11 x 16.8 x 18.1 x 8.12 x 11.3 x 49.5 x
Yield 6.21% 3.74% 3.39% 5.13% - -
Capitalization / Revenue 1.06 x 1.4 x 1.74 x 1.19 x 0.67 x 0.53 x
EV / Revenue 0.95 x 1.33 x 1.57 x 0.96 x 0.56 x 0.47 x
EV / EBITDA 5.87 x 8.65 x 9.73 x 4.59 x 4.01 x 8.17 x
EV / FCF 15.6 x 31.1 x 11.9 x 9.89 x -15.6 x -20.9 x
FCF Yield 6.42% 3.22% 8.37% 10.1% -6.41% -4.78%
Price to Book 2.33 x 3.17 x 3.5 x 2.07 x 1.33 x 1.22 x
Nbr of stocks (in thousands) 318,467 318,467 318,467 318,467 318,467 318,467
Reference price 2 112.7 160.6 191.8 136.5 87.77 82.99
Announcement Date 4/3/19 4/29/20 4/6/21 4/4/22 3/28/23 4/1/24
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 34,007 36,582 35,090 36,661 41,842 49,661
EBITDA 1 5,526 5,606 5,658 7,634 5,874 2,881
EBIT 1 4,863 4,811 4,909 6,873 5,068 1,965
Operating Margin 14.3% 13.15% 13.99% 18.75% 12.11% 3.96%
Earnings before Tax (EBT) 1 4,692 4,600 4,903 7,424 5,106 2,177
Net income 1 3,258 3,041 3,375 5,354 2,463 534
Net margin 9.58% 8.31% 9.62% 14.61% 5.89% 1.08%
EPS 2 10.23 9.549 10.60 16.81 7.734 1.677
Free Cash Flow 1 2,084 1,559 4,609 3,545 -1,509 -1,126
FCF margin 6.13% 4.26% 13.14% 9.67% -3.61% -2.27%
FCF Conversion (EBITDA) 37.71% 27.81% 81.47% 46.44% - -
FCF Conversion (Net income) 63.95% 51.27% 136.57% 66.21% - -
Dividend per Share 2 7.000 6.000 6.500 7.000 - -
Announcement Date 4/3/19 4/29/20 4/6/21 4/4/22 3/28/23 4/1/24
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3,433 2,638 6,013 8,429 4,408 2,886
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 2,084 1,559 4,609 3,545 -1,509 -1,126
ROE (net income / shareholders' equity) 22.4% 19.3% 20.1% 27.8% 11.7% 2.5%
ROA (Net income/ Total Assets) 13.8% 13.2% 12.4% 15.2% 9.6% 3.33%
Assets 1 23,608 22,958 27,117 35,229 25,657 16,016
Book Value Per Share 2 48.40 50.70 54.90 65.90 66.10 68.10
Cash Flow per Share 2 10.00 7.370 17.60 22.20 14.90 11.30
Capex 1 855 1,343 1,316 1,304 1,533 1,649
Capex / Sales 2.51% 3.67% 3.75% 3.56% 3.66% 3.32%
Announcement Date 4/3/19 4/29/20 4/6/21 4/4/22 3/28/23 4/1/24
1PKR in Million2PKR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GLAXOSMITHKLINE PAKISTAN LIMITED Stock GlaxoSmithKline Pakistan Limited
+20.98% 115M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GLAXO Stock
  4. Financials GlaxoSmithKline Pakistan Limited